ERBB2 and neoplasm: Furthermore, T-DXd demonstrated anti-tumor efficacy and durable responses in heavily pretreated patients across various tumor types with activating HER2 mutations, with no new safety signals observed in the clinical trial DESTINY-PanTumor01 (ClinicalTrials.gov identifier: NCT04639219).